Molecular pathways: Sterols and receptor signaling in cancer

Clinical Cancer Research

Volumn 20, Issue 1, 2014, Pages 28-34

  Gabitova, Linara ^a   Gorin, Andrey ^a,b   Astsaturov, Igor ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b KAZAN FEDERAL UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

7 DEHYDROCHOLESTEROL; EMOPAMIL; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; OXYSTEROL; STEROL; STEROL REGULATORY ELEMENT BINDING PROTEIN; VASCULOTROPIN RECEPTOR;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CHOLESTEROL TRANSPORT; ENDOSOME; GLIOBLASTOMA; HUMAN; LIPID METABOLISM; LIPOGENESIS; MEIOSIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHOLESTEROL; HOMEOSTASIS; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; STEROLS;

EID: 84892170909     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0122     Document Type: Article

References (62)

1. George KS, Wu S. Lipid raft: a floating island of death or survival. Toxicol Appl Pharmacol 2012;259:311-9.
2. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 2012;40:D109-14.
3. Acimovic J, Rozman D. Steroidal triterpenes of cholesterol synthesis. Molecules 2013;18:4002-17.
4. Janosi L, Li Z, Hancock JF, Gorfe AA. Organization, dynamics, and segregation of Ras nanoclusters in membrane domains. Proc Natl Acad Sci U S A 2012;109:8097-102.
5. Klippel A, Reinhard C, Kavanaugh WM, Apell G, Escobedo MA, Williams LT. Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways. Mol Cell Biol 1996;16:4117-27.
6. Reis-Sobreiro M, Roue G, Moros A, Gajate C, de la Iglesia-Vicente J, Colomer D, et al. Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma. Blood Cancer J 2013;3:e118.
7. Byskov AG, Andersen CY, Nordholm L, Thogersen H, Xia GL, Wassmann O, et al. Chemical-Structure of Sterols That Activate Oocyte Meiosis. Nature 1995;374:559-62.
8. Javitt NB. Bile acid synthesis from cholesterol: regulatory and auxiliary pathways. FASEB J 1994;8:1308-11.
9. Miller WL. Steroid hormone synthesis in mitochondria. Mol Cell Endocrinol 2013;379:62-73.
10. Porter FD, Herman GE. Malformation syndromes caused by disorders of cholesterol synthesis. J Lipid Res 2011;52:6-34.
11. Sikora DM, Pettit-Kekel K, Penfield J, Merkens LS, Steiner RD. The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. Am J Med Genet A 2006;140:1511-8.
12. Tierney E, Conley SK, Goodwin H, Porter FD. Analysis of short-term behavioral effects of dietary cholesterol supplementation in Smith- Lemli-Opitz syndrome. Am J Med Genet A 2010;152A:91-5.
13. Webb J. Cancer, its nature and its treatment. Lancet 1901;158:976-8.
14. Martinez-Botas J, Suarez Y, Ferruelo AJ, Gomez-Coronado D, Lasuncion MA. Cholesterol starvation decreases p34(cdc2) kinase activity and arrests the cell cycle at G2. FASEB J 1999;13:1359-70.
15. Martinez-Botas J, Ferruelo AJ, Suarez Y, Fernandez C, Gomez- Coronado D, Lasuncion MA. Dose-dependent effects of lovastatin on cell cycle progression. Distinct requirement of cholesterol and non-sterol mevalonate derivatives. Biochim Biophys Acta 2001; 1532:185-94.
16. Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov 2011;1:442-56.
17. Sundelin JP, Stahlman M, Lundqvist A, Levin M, Parini P, Johansson ME, et al. Increased expression of the very low-density lipoprotein receptor mediates lipid accumulation in clear-cell renal cell carcinoma. PloS ONE 2012;7:e48694.
18. Pitroda SP, Khodarev NN, Beckett MA, Kufe DW, Weichselbaum RR. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci U S A 2009;106:5837-41.
19. Huang WC, Li X, Liu J, Lin J, Chung LW. Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res 2012;10:133-42.
20. Lee BH, Taylor MG, Robinet P, Smith JD, Schweitzer J, Sehayek E, et al. Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. Cancer Res 2013;73:1211-8.
21. Rudling MJ, Angelin B, Peterson CO, Collins VP. Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement. Cancer Res 1990;50:483-7.
22. Huang J, Das SK, Jha P, Al Zoughbi W, Schauer S, Claudel T, et al. The PPARalpha agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism. Biochim Biophys Acta 2013;1831:1555-65.
23. Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, et al. Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation. Cancer Discov 2013;3:96-111.
24. Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR. Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res 2002;62:2227-31.
25. Scita G, Di Fiore PP. The endocytic matrix. Nature 2010;463:464-73.
26. Zwaenepoel K, Goris J, Erneux C, Parker PJ, Janssens V. Protein phosphatase 2A PR130/B''alpha1 subunit binds to the SH2 domaincontaining inositol polyphosphate 5-phosphatase 2 and prevents epidermal growth factor (EGF)-induced EGF receptor degradation sustaining EGF-mediated signaling. FASEB J 2010;24:538-47.
27. Vieira AV, Lamaze C, Schmid SL. Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 1996;274:2086-9.
28. Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell 2008;15:209-19.
29. Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y, et al. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal 2010;3:ra67.
30. Vinci G, Xia X, Veitia RA. Preservation of genes involved in sterol metabolism in cholesterol auxotrophs: facts and hypotheses. PloS ONE 2008;3:e2883.
31. Mo C, Valachovic M, Randall SK, Nickels JT, Bard M. Protein-protein interactions among C-4 demethylation enzymes involved in yeast sterol biosynthesis. Proc Natl Acad Sci U S A 2002;99:9739-44.
32. Liu XY, Dangel AW, Kelley RI, Zhao W, Denny P, Botcherby M, et al. The gene mutated in bare patches and striated mice encodes a novel 3beta-hydroxysteroid dehydrogenase. Nat Genet 1999;22:182-7.
33. McDaniel FK, Molden BM, Mohammad S, Baldini G, McPike L, Narducci P, et al. Constitutive cholesterol-dependent endocytosis of melanocortin-4 receptor (MC4R) is essential to maintain receptor responsiveness to alpha-melanocyte- stimulating hormone (alpha- MSH). J Biol Chem 2012;287:21873-90.
34. Sorrentino V, Nelson JK, Maspero E, Marques AR, Scheer L, Polo S, et al. The LXR-IDOL axis defines a clathrin, caveolae, and dynaminindependent endocytic route for LDLR internalization and lysosomal degradation. J Lipid Res 2013;54:2174-84.
35. Mbikay M, Mayne J, Chretien M. PCSK9, an enzyme turned escort protein: hepatic and extra hepatic functions. J Diabetes 2013;5:391-405.
36. Nohturfft A, Yabe D, Goldstein JL, Brown MS, Espenshade PJ. Regulated step in cholesterol feedback localized to budding of SCAP from ER membranes. Cell 2000;102:315-23.
37. Yokoyama C, Wang X, Briggs MR, Admon A, Wu J, Hua X, et al. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 1993; 75:187-97.
38. El Roz A, Bard JM, Huvelin JM, Nazih H. The anti-proliferative and proapoptotic effects of the trans9, trans11 conjugated linoleic acid isomer on MCF-7 breast cancer cells are associated with LXR activation. Prostaglandins Leukot Essent Fatty Acids 2013;88:265-72.
39. Scotti E, Calamai M, Goulbourne CN, Zhang L, Hong C, Lin RR, et al. IDOL stimulates clathrin-independent endocytosis and multivesicular body-mediated lysosomal degradation of the low-density lipoprotein receptor. Mol Cell Biol 2013;33:1503-14.
40. Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, Su JL, et al. Activation of the nuclear receptor LXR by oxysterols defines anew hormone response pathway. J Biol Chem 1997;272:3137-40.
41. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996;383:728-31.
42. Cooper MK, Wassif CA, Krakowiak PA, Taipale J, Gong R, Kelley RI, et al. A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat Genet 2003;33:508-13.
43. Nachtergaele S, Mydock LK, Krishnan K, Rammohan J, Schlesinger PH, Covey DF, et al. Oxysterols are allosteric activators of the oncoprotein Smoothened. Nat Chem Biol 2012;8:211-20.
44. Byskov AG, Andersen CY, Leonardsen L, Baltsen M. Meiosis activating sterols (MAS) and fertility in mammals and man. J Exp Zool 1999; 285:237-42.
45. Herman GE, Kelley RI, Pureza V, Smith D, Kopacz K, Pitt J, et al. Characterization of mutations in 22 females with X-linked dominant chondrodysplasia punctata (Happle syndrome). Genet Med 2002;4:434-8.
46. de Medina P, Paillasse MR, Segala G, Poirot M, Silvente-Poirot S. Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands. Proc Natl Acad Sci U S A 2010;107:13520-5.
47. de Medina P, Paillasse MR, Segala G, Voisin M, Mhamdi L, Dalenc F, et al. Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties. Nat Commun 2013;4:1840.
48. de Medina P, Paillasse MR, Payre B, Silvente-Poirot S, Poirot M. Synthesis of new alkylaminooxysterols with potent cell differentiating activities: identification of leads for the treatment of cancer and neurodegenerative diseases. J Med Chem 2009;52:7765-77.
49. Salem NE, Saito M, Kasama Y, Ozawa M, Kawabata T, Harada S, et al. Genomic polymorphisms in 3beta-hydroxysterol Delta24-reductase promoter sequences. Microbiol Immunol 2013;57:179-84.
50. Wu C, Miloslavskaya I, Demontis S, Maestro R, Galaktionov K. Regulation of cellular response to oncogenic and oxidative stress by Seladin-1. Nature 2004;432:640-5.
51. Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008;134:97-111.
52. Vedin LL, Gustafsson JA, Steffensen KR. The oxysterol receptors LX Ralpha and LXRbeta suppress proliferation in the colon. Mol Carcinog 2012;52:835-44.
53. Uno S, Endo K, Jeong Y, Kawana K, Miyachi H, Hashimoto Y, et al. Suppression of beta-catenin signaling by liver X receptor ligands. Biochem Pharmacol 2009;77:186-95.
54. Lo Sasso G, Bovenga F, Murzilli S, Salvatore L, Di Tullio G, Martelli N, et al. Liver x receptors inhibit proliferation of human colorectal cancer cells and growth of intestinal tumors in mice. Gastroenterology 2013; 144:1497-507.
55. Murtola TJ, Syvala H, Pennanen P, Blauer M, Solakivi T, Ylikomi T, et al. The importance of LDL and cholesterol metabolism for prostate epithelial cell growth. PloS ONE 2012;7:e39445.
56. Campia I, Lussiana C, Pescarmona G, Ghigo D, Bosia A, Riganti C. Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells, without decreasing the beneficial effects on cholesterol synthesis. Br J Pharmacol 2009;158:1777-86.
57. Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA, et al. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A 2010;107:15051-6.
58. Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011;146:408-20.
59. Tang JJ, Li JG, Qi W, Qiu WW, Li PS, Li BL, et al. Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. Cell Metab 2011;13:44-56.
60. Walker AK, Jacobs RL, Watts JL, Rottiers V, Jiang K, Finnegan DM, et al. A conserved SREBP-1/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. Cell 2011;147:840-52.
61. Kamisuki S, Mao Q, Abu-Elheiga L, Gu Z, Kugimiya A, Kwon Y, et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem Biol 2009;16:882-92.
62. Radhakrishnan A, Ikeda Y, Kwon HJ, Brown MS, Goldstein JL. Sterolregulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. Proc Natl Acad Sci U S A 2007;104:6511-8.